Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis

Trial Profile

Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Centella asiatica/Echinacea purpurea/Sambucus nigra (Primary)
  • Indications Atrophic vaginitis; Vaginitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Izun Pharma
  • Most Recent Events

    • 13 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 13 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.
    • 07 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top